Michael Heffernan
Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.
Net worth: 2 M $ as of 2024-05-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul Wotton | M | 63 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | 7 years |
Gregory Bailey | M | 68 | 10 years | |
Julia Gregory | F | 71 | 7 years | |
Jennifer Good | F | 59 | 13 years | |
Michael Rogers | M | 64 | 8 years | |
Vladimir Coric | M | 53 | 9 years | |
Ed Mathers Mathers | M | 64 | 12 years | |
Peter Barrett | M | 71 |
Indalo Therapeutics, Inc.
Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | 7 years |
John Childs | M | 81 | 10 years | |
Steven Gilman | M | 71 | 8 years | |
Robert Hugin | M | 69 | 4 years | |
George Clark | M | - | 5 years | |
Irina Antonijevic | M | 59 | 2 years | |
Shirley Kuhlmann | F | 40 | 6 years | |
Kimberly Gentile | F | 56 | 9 years | |
Garen Bohlin | M | 76 |
PreCision Dermatology, Inc.
PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | 12 years |
Kishan Mehta | M | 38 | 3 years | |
Douglas R. Carlson | M | 45 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | 2 years |
Terrence Connolly | M | - |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | - |
Douglas G. Gray | M | - | - | |
Mary Dooley | F | 43 | 6 years | |
Matthew Buten | M | 62 | 3 years | |
Gastón Ortega | M | - | 2 years | |
Paloma Moraleda | F | - | 2 years | |
Irfan Qureshi | M | - | - | |
Brendan St Amant | M | - | 3 years | |
Jennifer Porcelli | F | - | 2 years | |
Gino Santini | M | 67 | 12 years | |
John Freund | M | 70 | 10 years | |
Rita Balice-Gordon | M | 63 | 4 years | |
Myles Wolf | M | 53 | 4 years | |
Noel Barnard | M | - | 11 years | |
Mark Hensley | M | - | 8 years | |
Scott Dreyer | M | 52 | 6 years | |
Scott Sudduth | M | - | 6 years | |
Thomas J. Adam | M | - | 7 years | |
Thomas Sciascia | M | 70 | 13 years | |
Dominick Colangelo | M | 60 | 4 years | |
Gwen Melincoff | M | 72 | 7 years | |
Ronald Frieson | M | 65 | 3 years | |
Lori Kunkel | M | 66 |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | - |
LeAnne Zumwalt | F | 65 | 3 years | |
Megan M. Dow | M | - | 4 years | |
Adrian Adams | M | 73 | 6 years | |
Richard Shea | M | 72 | 7 years | |
James Cassella | M | 69 | 4 years | |
Anne VanLent | F | 76 | 6 years | |
Thomas Holm Pedersen | M | - |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | 9 years |
John Fallon | M | 76 | 8 years | |
Terry Connolly | F | - |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | 3 years |
Neil McFarlane | M | 51 | 2 years | |
Nick Leschly | M | 51 | 7 years | |
Chris Barrett | M | - | - | |
Thomas J. O'Brien | M | 75 |
University of Connecticut
| 38 years |
Thomas Kongstad Petersen | M | - |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | - |
Jeremy Springhorn | M | 61 |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | 5 years |
Jon Blaskovich | M | - | - | |
Maryellen McQuade | F | - | - | |
Sabine Dandiguian | F | - |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | - |
Scott Morenstein | M | 48 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | - |
Josh Richardson | M | 42 |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | - |
Tracey Vetterick | F | - | 2 years | |
Morten Graugaard Døssing | M | - |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | - |
Melissa Beiner | M | - | - | |
Ulf Meier-Kriesche | M | - | 7 years | |
Rita L. Mannella | F | - | 7 years | |
Ben Auspitz | M | - |
Indalo Therapeutics, Inc.
Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Tarnok | M | 69 | 9 years | |
Alastair Stuart McEwan | M | 69 | 3 years | |
Ira Duarte | F | 55 | 7 years | |
Jodie Morrison | F | 48 | 4 years | |
Craig Collard | M | 58 | 13 years | |
Mette Agger | F | 59 | 9 years | |
Mark Enyedy | M | 60 | 4 years | |
Aoife Brennan | M | 48 | 8 years | |
Gregory Madison | M | 57 | 4 years | |
Eran Nadav | M | 55 | 7 years | |
Gary H. Rabin | M | 58 | 7 years | |
Antoine Awad | M | 44 | 6 years | |
Johnny Stilou | M | 57 | 8 years | |
Joseph Ciaffoni | M | 53 | 7 years | |
Jeffrey M. Nugent | M | 76 |
PreCision Dermatology, Inc.
PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | 4 years |
Declan Doogan | M | 72 | 8 years | |
David Spellman | M | 48 | 3 years | |
Elyse Stock | M | 66 | 5 years | |
John D. Weinberg | M | 57 | 6 years | |
Patrick Heron | M | 53 |
PreCision Dermatology, Inc.
PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | 8 years |
Jason Amello | M | 55 | 7 years | |
Masao Yoshida | M | - | - | |
Michael P. Culmo | M | - |
University of Connecticut
| 6 years |
Jane C. I. Hirsh | F | - |
Onset Dermatologics LLC
Onset Dermatologics LLC Pharmaceuticals: MajorHealth Technology Onset Dermatologics LLC develops and markets prescription product for skin disorders. The company was founded in 2005 and is headquartered in Cumberland, RI. | - |
Scott A. Holmes | M | 50 | 3 years | |
Edward Myles | M | 52 | 3 years | |
Amy Sullivan | F | 54 | 4 years | |
Mark Militello | M | - |
University of Connecticut
| 8 years |
Eric Aguiar | M | 62 | 4 years | |
Tim Heaney | M | - |
University of Connecticut
| 7 years |
Brian Adams | M | 50 | 4 years | |
Charles Conway | M | 62 | 5 years | |
Mary E. Olson | F | - |
University of Connecticut
| 6 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 66 | 66.00% |
Denmark | 16 | 16.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael Heffernan
- Personal Network